LifeMD, Inc. announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. Dr. MacRae is a cardiologist and geneticist whose clinical interests include exploring how research findings, including genomics discoveries, can be efficiently implemented into clinical care. Currently, he is Vice Chair for Scientific Innovation at the Department of Medicine at Brigham and Women?s Hospital, Professor of Medicine at Harvard Medical School, an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member at the Harvard Stem Cell Institute.

His research focuses on the biology and genomics of cardiovascular disease, and he is particularly interested in the interface between technology and biomedicine. Since 2016, Dr. MacRae has been the leader of the One Brave Idea initiative to advance understanding of how technology can inform disease and disease management. This work was funded by the American Heart Association, Verily, AstraZeneca and Quest Diagnostics.

He has worked with multiple technology companies on novel sensors and their utility in health and wellness, and is currently the Principal Investigator of Apple?s Heart and Movement Study. Dr. MacRae has served as a scientific advisor to various pharmaceutical, data and technology companies in the U.S. and Europe, ranging from global leaders to venture-backed companies, and has also served on the advisory boards of several investment firms. He is a co-founder of Atman Health and Tanaist. Dr. MacRae received his medical degree from University of Edinburgh Medical School and a Ph.D. in Human Molecular Genetics at the University of London.

He is board certified in internal medicine and cardiovascular disease.